Related Experiment Video

Updated: Apr 19, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K

Benefits of timely basal insulin control in patients with type 2 diabetes

Dragana Lovre1, Vivian Fonseca1

  • 1Tulane University Health Sciences Center, New Orleans, LA.

Journal of Diabetes and Its Complications
|December 25, 2014
PubMed

Insights

Early insulin therapy for diabetes can prevent complications and induce remission. Basal insulin analogs, especially when initiated early and combined with incretin agents, offer effective glucose control with reduced risks compared to delayed or other insulin types.

Area of Science:

  • Endocrinology and Metabolism
  • Diabetes Mellitus Management
  • Pharmacotherapy

Background:

  • Underdiagnosis and undertreatment of diabetes lead to prolonged hyperglycemia and irreversible complications.
  • Early glucose control is crucial for preventing macrovascular and microvascular complications, with limited benefit from late-stage tight control.

Purpose of the Study:

  • To evaluate the efficacy and safety of early insulin therapy, particularly basal insulin analogs, in managing diabetes.
  • To explore the role of insulin therapy in achieving diabetes remission and maintaining glycemic control.
  • To assess the benefits of patient self-titration algorithms and combination therapy with incretin agents.

Main Methods:

  • Review of current literature on insulin therapy for type 2 diabetes.
  • Comparative analysis of basal insulin analogs versus NPH and pre-mixed insulins.
  • Examination of data on incretin agents in combination with basal insulin.

Main Results:

  • Insulin therapy provides the most potent antihyperglycemic effect and can induce diabetes remission in newly diagnosed patients.
  • Early second-line basal insulin therapy is more effective for durable A1C control (≤7%) than delayed treatment.
  • Basal insulin analogs are associated with lower risks of hypoglycemia and weight gain compared to older insulin formulations.
  • Patient self-titration algorithms improve glycemic control and reduce healthcare provider burden.
  • Combination therapy with incretin agents and basal insulin enhances glycemic control with minimal added risk of hypoglycemia or weight gain.

Conclusions:

  • Early initiation of basal insulin therapy, preferably using analogs, is recommended for optimal and sustained glycemic control in diabetes.
  • Basal insulin analogs offer a safer and more effective alternative to older insulin types.
  • Combination therapy and patient self-management strategies represent valuable advancements in diabetes care.
Keywords:
Basal insulinGlycemic goalsInsulin initiationInsulin titrationInsulin treatmenttype 2 diabetes mellitus

More Related Videos

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.9K
Hyperinsulinemic-Euglycemic Clamp in the Conscious Rat11:12

Hyperinsulinemic-Euglycemic Clamp in the Conscious Rat

Published on: February 7, 2011

54.6K

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
1.2K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.9K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
6.5K
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
2